Friday, July 31, 2009

Dr Robert Kellers Patent Highlights

In summary, it has been demonstrated that decreased levels of glutathione may be a result of various types of prolonged stress, increased free radical formation and hyperactivity of the immune system. These factors in turn compromise the health of mammalian cells. Despite the apparent importance of adequate glutathione levels, little emphasis has heretofore been placed on replacing depleted stores. Some glutathione comes from the diet but the majority is made in the liver.

Initial studies have shown that the systemic administration of the inventive composition also increases energy in people without illness who are exposed to increased stress.

Our studies have shown systemic administration of the composition results in an improvement in T lymphocyte function which correlates directly with an increased intra lymphocyte GSH. In addition, our data demonstrates that the inventive composition and method shifts the T-cell balance from TH2 (allergy producing) to TH1 (viral/tumor killing) and the increases intra lymphocyte GSH correlate directly with decreased levels of IgE the immunoglobulin associated with allergies. Further studies have revealed the following:

Systemic administration of the composition increases natural killer cell function which is considered a primitive first line of cellular immune defense. Systemic administration of the composition decreases serum cholesterol and triglycerides of between 10 and 20% in patients with a variety of hyperlipidemias and a decrease in myalgias associated with illness and exercise and improved muscle recovery after exercise. Systemic administration of the composition decreases fatigue in patients suffering from a variety of illnesses including but not limited to chronic viral infections, HIV, hepatitis C, chronic fatigue, immuno deficiency syndrome, immune deficiencies, cancer, B-cell malignancies, including lymphomas, chronic leukemia, myeloma Waldenstrom's and MGUS.

This makes the composition function as both a pharmaceutical and a therapeutic substance for patients suffering from the debilitating conditions. Initial studies have shown that the systemic administration of the inventive composition also increases energy in people without illness who are exposed to increased stress. As such, the combination formulated will improve hepatic function in conditions associated with chronic viral infections, as well as any condition associated with increased hepatic work or stress. Thus by the present invention its advantages will be realized and although preferred embodiments have been disclosed and described in detail herein, its scope should not be limited thereby rather its scope should be determined by that of the appended claims.

Dr. Robert Keller's Patent
Amy McFarland tells it like it is. No fluff, no filler, and no rehashed material to beef up a sorely lacking product. MaxGXL is the product!
Max International is now the company to be in to build a real business with a patented and varifiable product!

No comments:

Post a Comment